Updated:
Newsight Tech Angels
Newsight Tech Angels is an angel investor group based in Tokyo, Japan, founded in 2022. The group invests in life sciences and financial industries.
Newsight Tech Angels
Newsight Tech Angels is an angel investor group based in Tokyo, Japan, founded in 2022. The group invests in life sciences and financial industries. Newsight Tech Angels has made 10 investments, including a March 24, 2026, investment in Aptadel Therapeutics as part of their Bridge.
General information
Firm type
Private Equity
Year founded
2022
AUM
Undisclosed
Location
Region
Asia
Country
Japan
City
Tokyo
Corporate office
2-28-4 Nihonbashi, Chuo-ku, Tokyo, 103-0004, Japan
Principals
Toru Seo
Representative Director
Sector focus
Frequently asked questions
Who runs investment decisions at Newsight Tech Angels?
Toru Seo serves as Representative Director and leads the firm, which operates with a team of life-science and finance professionals. The firm has not disclosed a separate investment committee or additional named investment partners beyond Seo.
Is Newsight Tech Angels structured as a venture capital fund or an angel syndicate?
It operates as an angel investment fund with a US-domiciled subsidiary, Newsight Tech Angels LLC. The April 2024 memorandum with Taisho Pharmaceutical to create a new fund suggests it can deploy both proprietary capital and co-investment vehicles alongside Japanese corporate partners.
What investment stages does Newsight Tech Angels typically target?
The firm targets early-stage biotechnology and healthcare companies. Confirmed deals include a university spinout (CrestecBio) and US startups focused on drug discovery and gene delivery, indicating a focus on preclinical and early-clinical stage assets.
How is Newsight Tech Angels related to Taisho Pharmaceutical?
In April 2024, Newsight Tech Angels and Taisho Pharmaceutical signed a memorandum of understanding to establish a new fund. The announcement indicates a collaborative structure where the firm originates deals and Taisho participates as an anchor corporate limited partner or co-investor.
Does Newsight Tech Angels invest only in US companies?
While the firm uses a Delaware LLC to source US deals, it also invests in Japanese startups — its July 2023 investment in CrestecBio, a University of Tsukuba spinout, confirms domestic Japanese biotech exposure alongside US positions such as GigaMune and TRIO Pharmaceuticals.
What is Newsight Tech Angels' regulatory status in Japan?
In August 2024, the firm received certification as a 'Certified External Management Resource Utilization Promotion Investment Business Operator,' a Japanese government designation that may facilitate co-investment from domestic institutional partners and align with policies encouraging open innovation.
Which sectors does Newsight Tech Angels explicitly focus on?
The firm concentrates on biotechnology and healthcare. Announcements all fall within drug discovery, gene delivery, and life-science tools — there is no evidence of investment in digital health apps, medical devices outside biotech, or adjacent healthcare services that are not research-driven.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: